François Briand, Director of Research and Business Development at Physiogenex, will be giving a talk during the HFpEF Drug Discovery & Development Summit 2022, a digital event, on Wednesday, January 26, 2022, 18:30 CET time / 12.30 EST time / 9:30 PT time.
The HFpEF Drug Discovery & Development Summit is the first industry specific forum exclusively focused on drug discovery and translation in HFpEF, and its relationship with subpopulations with metabolic syndromes and co-morbidities.
This presentation will be dedicated to Novel Animal Models of HFpEF with Metabolic Comorbidities for Translational Drug Efficacy Studies.
In this presentation, François Briand will:
-Discuss the limitations of high fat diet-induced obese mouse and rat models for HFpEF
-Describe the Spontaneously Diabetic Torii (SDT) fatty rat and the LundMetS rat models to target HFpEF in the context of diabetic nephropathy and NASH
-Present the free-choice diet-induced obese NASH hamster, a preclinical model with severe diastolic dysfunction and restrictive profile
Feel free to contact us if you wish to set-up an appointment with Dr. Briand and/or discuss your drug development projects with us.
Physiogenex is a leading preclinical research organization providing non clinical services in metabolic disorders and complications.
We offer in vivo translational diseases models as well as ex vivo assays to support efficacy and pharmacological assays. We have a strong expertise on metabolic diseases, diabetes, insulin resistance, obesity, dyslipidemia, liver diseases (NASH to fibrosis), cardiovascular and renal complications.